DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Girentuximab
Girentuximab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Download
International Nonproprietary Names for Pharmaceutical Substances (INN)
The Two Tontti Tudiul Lui Hi Ha Unit
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Multimodal Image-Guided Surgery of HER2-Positive Breast Cancer Using [111In]In-DTPA-Trastuzumab-Irdye800cw in an Orthotopic Brea
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: the ARISER Randomized Clinical Trial
(INN) for Biological and Biotechnological Substances
Orphan Drug Dummy File
Prescrire's Response
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
The Chemistry Behind Adcs
(INN) for Biological and Biotechnological Substances
WO 2014/075788 Al 22 May 2014 (22.05.2014) P O P C T
Ep 2739649 B1
Top View
WO 2018/161000 Al 07 September 2018 (07.09.2018) W !P O PCT
Half-Yearly Financial Report 2021 Key Figures
Targeted Dual-Modality Imaging in Renal Cell Carcinoma: an Ex Vivo Kidney Perfusion Study
A61K9/51 (2006.01) — with International Search Report (Art
The Advancement of Immuno-PET Into Clinical Use Brian D
Improved Image Reconstruction of 89Zr-Immunopet Studies Using A
PDF Hosted at the Radboud Repository of the Radboud University Nijmegen
Annual Report 2020 Key Figures
Improving Patient Selection for Adjuvant Therapy in High-Risk Renal Cell Carcinoma
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Adjuvant Weekly Girentuximab Following
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Assessment of the Evolution of Cancer Treatment Therapies
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma the ARISER Randomized Clinical Trial
(12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
Genitourinary Cancer—Kidney and Bladder
Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Įsakymas
Half-Yearly Financial Report 2018 Key Figures
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Potential Role of 124I-Girentuximab in the Presurgical Diagnosis of Clear-Cell Renal Cell Cancer
WO 2017/096163 Al 8 June 2017 (08.06.2017) W P O P C T
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
[89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Neeta Pandit-Taskar, MD
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
International Journal of Current Advanced Research
Supplemental Table 1. 89Zr-Labeled Biopharmaceuticals in Completed Or Ongoing Clinical Trials
Oncology Drugs in the Pipeline
Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
WO 2013/119960 A2 15 August 2013 (15.08.2013) P O P C T
(INN) for Biological and Biotechnological Substances
The Chemistry Behind Adcs
[89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma Anchal
Half Yearly Financial Report 2019 Key Figures
Which Are the Antibodies to Watch in 2012?
Ep 3088005 A1
Oncology Drugs in the Pipeline
Half-Yearly Financial Report 2020 Key Figures
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Girentuximab (Rencarex) for Renal Cell Carcinoma
The Clinical Role of Nuclear Imaging in Immunotherapeutic Drug Development